These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11677932)

  • 1. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
    Merlé Y; Tod M
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):363-88. PubMed ID: 11677932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.
    Ogungbenro K; Graham G; Gueorguieva I; Aarons L
    J Biopharm Stat; 2008; 18(2):342-58. PubMed ID: 18327725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.
    McGree JM; Eccleston JA; Duffull SB
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):101-23. PubMed ID: 19224348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.
    Merlé Y; Mallet A; Schmautz E
    J Pharmacokinet Biopharm; 1999 Oct; 27(5):531-54. PubMed ID: 10948697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal design of mixed-effects PK/PD models based on differential equations.
    Wang Y; Eskridge KM; Nadarajah S
    J Biopharm Stat; 2012; 22(1):180-205. PubMed ID: 22204534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
    Tod M; Mentré F; Merlé Y; Mallet A
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):689-716. PubMed ID: 10485081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.
    Dette H; Pepelyshev A; Wong WK
    J Pharmacokinet Pharmacodyn; 2012 Jun; 39(3):295-311. PubMed ID: 22614634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.
    Nyberg J; Bazzoli C; Ogungbenro K; Aliev A; Leonov S; Duffull S; Hooker AC; Mentré F
    Br J Clin Pharmacol; 2015 Jan; 79(1):6-17. PubMed ID: 24548174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Fisher information matrix approximation methods in population optimal design calculations.
    Strömberg EA; Nyberg J; Hooker AC
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):609-619. PubMed ID: 27804003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.